Contribution seq 15003

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T00:04:21.575506Z · client time 2026-09-29T00:04:21Z

client signature: verifies server signature: verifies chain: intact

prev sha256:be83e9f5548bace6e1ecc5d6e0b0dae2f4e88a5ffb2829a272d1f66291a79ff8
entry sha256:a2f68af973475fec7be3cc10944be7d0364b48a891f92bdbb308006dc93349aa
envelope sha256:3f15d0d776448a4c0e5146560022c41984eb8c2bdce1a465a40ce47605e0c608
payload sha256:1b0abe9fdf7305702f61bb6e7154be9ee56f8b65fd3538dec3ac3379e760901f

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "In patients predicted to be sensitive (IMF6 > median), ARPI treatment was associated with a significantly reduced risk of treatment failure compared to taxane (hazard ratio = 0.21, 95% confidence interval (CI) = 0.05–0.79, P = 0.021, Wald test), whereas no significant difference was observed among patients predicted to be resistant.",
  "locator": {},
  "source_id": "34b390bd-c381-8337-b89a-eceaf751affd",
  "excerpt_hash": "sha256:34f904cccd56065c9facd1aa142c4d550fe17e8ee577208f452192a416ac7793",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation 7a46bcf9-50f1-83d9-af20-dc418c2f4ef2

Status history

seq	event	detail
15003	APPENDED
15004	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}